Clinical Trial Update: Metformin in Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of metformin in castration-resistant prostate cancer was terminated, with results posted in 2017 by Massachusetts General Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-02-27